71 results about "Gastrointestinal motility disorder" patented technology

Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders are described. The compositions feature peptides that activate the guanylate cyclase C (GC-C) receptor.

The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective agonists of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Such compounds are useful as medicaments for treatment and prevention of a range of medical conditions characterized by disturbed gastrointestinal motility including, but not limited to, post-surgical gastroparesis and post-operative ileus in combination with opioid-induced bowel dysfunction. These agents are effective for multiple disorders at dose levels equivalent to those required to treat a single disorder.

Compositions of domperidone formulated for transmucosal delivery are provided. Also provided are methods for the treatment of nausea, vomiting, and gastrointestinal motility disorders, and methods for the enhancement of breast milk production. The methods utilize domperidone compositions formulated for transmucosal administration, administered to patients in an amount effective to treat nausea, vomiting, or gastrointestinal motility disorders, or to enhance breast milk production.

The present invention provides conformationally-defined macrocyclic compounds that bind to and / or are functional modulators of the motilin receptor including subtypes, isoforms and / or variants thereof. These macrocyclic compounds, at a minimum, possess adequate pharmacological properties to be useful as therapeutics for a range of disease indications. In particular, these compounds are useful for treatment and prevention of disorders characterized by hypermotilinemia and / or gastrointestinal hypermotility, including, but not limited to, diarrhea, cancer treatment-related diarrhea, cancer-induced diarrhea, chemotherapy-induced diarrhea, radiation enteritis, radiation-induced diarrhea, stress-induced diarrhea, chronic diarrhea, AIDS-related diarrhea, C. difficile associated diarrhea, traveller's diarrhea, diarrhea induced by graph versus host disease, other types of diarrhea, dyspepsia, irritable bowel syndrome, chemotherapy-induced nausea and vomiting (emesis) and post-operative nausea and vomiting and functional gastrointestinal disorders. In addition, the compounds possess utility for the treatment of diseases and disorders characterized by poor stomach or intestinal absorption, such as short bowel syndrome, celiac disease and cachexia. The compounds also have use for the treatment of inflammatory diseases and disorders of the gastrointestinal tract, such as inflammatory bowel disease, ulcerative colitis, Crohn's disease and pancreatitis. Accordingly, methods of treating such disorders and pharmaceutical compositions including compounds of the present invention are also provided.

A digestive tract power detection system relates to the field of digestive tract power detection, including an eight-lead gastrointestinal electrogram detection system, a pressure detection system and a software control system. The pressure detection system includes an esophageal pressure detection system and anorectal pressure detection system. Through the software control system, the instrument conducts two-way data transmission between the eight-lead gastrointestinal electrogram detection system, esophageal pressure detection system and anorectal pressure detection system, and realizes the collection of esophageal dynamic detection, anorectal dynamic detection and eight-lead gastrointestinal electrogram detection Digestive tract motility detection system with three functions in one. The best effect is that the digestive tract dynamic detection system embodies the highly integrated circuit technology of the gastrointestinal electrogram detection system and pressure detection system, and integrates signal processing circuits such as signal amplification, active filtering, feedback and control, power amplification and A / A series of circuits such as D conversion are integrated on a computer-specific detection card; and many information processing and automatic control technologies such as electrophysiological signal processing technology, pressure source constant pressure control technology of pressure detection system, automatic control software and data analysis are adopted. Processing technology and database management technology bring great convenience to the diagnosis and research of digestive tract motility diseases, and more accurate and comprehensive diagnosis and research of digestive tract motility diseases.

Compounds are provided which are useful in treating disorders of gastrointestinal motility and which have the structureor a pharmaceutically acceptable salt thereof, a prodrug ester thereof, and all stereoisomers thereof,wherein R1 and R2 are the same or different and are independently selected from hydrogen, alkyl, aryl, cycloalkyl, alkenyl, alkynyl, arylalkyl, heteroaryl, heteroarylalkyl or heterocycloalkyl;Z is selected from —CON(R4)R4a, —CO2R4, —SO2N(R4)R4a, —SO2R4, CN, andR4 and R4a are the same or different and are independently selected from hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl or R4 and R4a can be joined together to form a heterocycle.R4b is selected from hydrogen, halogen, hydroxyl, CN, OCF3, CF3, CONH2, SONH2, SO2CH3, NHCOCH3 or NHCO2CH3; andQ is a substituted bicyclic heterocycle.A method for using such compounds for treating disorders of gastrointestinal motility is also provided.

The present invention relates to a novel quinoline derivative compound, an optical isomer thereof, a pharmaceutically acceptable salt thereof, and a hydrate or a solvate thereof. The novel quinoline derivative compound, the optical isomer thereof, the pharmaceutically acceptable salt thereof, and the hydrate or the solvate thereof accelerates gastrointestinal movement, and thus can effectively prevent or treat gastrointestinal motility disorders.

The present invention provides conformationally-defined macrocyclic compounds that bind to and / or are functional modulators of the motilin receptor including subtypes, isoforms and / or variants thereof. These macrocyclic compounds, at a minimum, possess adequate pharmacological properties to be useful as therapeutics for a range of disease indications. In particular, these compounds are useful for treatment and prevention of disorders characterized by hypermotilinemia and / or gastrointestinal hypermotility, including, but not limited to, diarrhea, cancer treatment-related diarrhea, cancer-induced diarrhea, chemotherapy-induced diarrhea, radiation enteritis, radiation-induced diarrhea, stress-induced diarrhea, chronic diarrhea, AIDS-related diarrhea, C. difficile associated diarrhea, traveller's diarrhea, diarrhea induced by graph versus host disease, other types of diarrhea, dyspepsia, irritable bowel syndrome, chemotherapy-induced nausea and vomiting (emesis) and post-operative nausea and vomiting and functional gastrointestinal disorders. In addition, the compounds possess utility for the treatment of diseases and disorders characterized by poor stomach or intestinal absorption, such as short bowel syndrome, celiac disease and cachexia. The compounds also have use for the treatment of inflammatory diseases and disorders of the gastrointestinal tract, such as inflammatory bowel disease, ulcerative colitis, Crohn's disease and pancreatitis. Accordingly, methods of treating such disorders and pharmaceutical compositions including compounds of the present invention are also provided.

The present invention relates to a composition containing a Pinelliae Rhizoma and Scutellariae Radix extract as an active ingredient to reduce side effects caused by an anticancer drug, and more particularly, a composition for reducing side effects such as damage to the gastrointestinal tract and a gastrointestinal motility disorder by administering an anticancer drug. The composition of the present invention has an excellent effect of reducing side effects in administration of the anticancer drug through an antioxidative function, and synthesis, secretion and control of the functions of gastrin and serotonin producing gastrointestinal endocrine cells.

The invention discloses a fructus aurantii quality marker and a screening method thereof. The method includes the steps that firstly, chemical phenotypes and difference components of Jiangxi genuine fructus aurantii and non-genuine fructus aurantii are compared, and finally, a chemical component group with the stomach invigorating effect in fructus aurantii is determined through pharmacological research on serum medicinal chemistry and in-vitro, in-vivo and virtual stomach invigorating activity screening. It is found that intragastric administration through the fructus aurantii extract can remarkably resist atropine-induced gastrointestinal motility disorder, the chemical component group capable of reflecting clinical medication effectiveness of fructus aurantii is finally determined through screening of the stomach invigorating activity of in-vitro chemical components, and the chemical component group can serve as a quality marker of fructus aurantii, and the quality control of the fructus aurantii based on the medicinal components is realized. According to the invention, the traditional Chinese medicine quality control problems that the quality of fructus aurantii medicinal materials is uneven, the clinical efficacy is unstable, the traditional fructus aurantii quality standard does not reflect the unrelated efficacy and the like are solved.